Skip to content
Biodatica
Start free

UCB Biopharma SRL

Peoria, Arizona

OncologyFiled/ApprovedListed · UCBJY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

3d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Dec 10, 2025

    Psoriatic Arthritis, Axial Spondyloarthritis · RECRUITING · sponsor: UCB Biopharma SRL · A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

    ClinicalTrials.gov · NCT07290036 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Nov 5, 2025

    Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa · RECRUITING · sponsor: UCB Biopharma SRL · A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

    ClinicalTrials.gov · NCT06888193 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Apr 7, 2025

    Hidradenitis Suppurativa · RECRUITING · sponsor: UCB Biopharma SRL · A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

    ClinicalTrials.gov · NCT06921850 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Mar 11, 2025

    Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis · RECRUITING · sponsor: UCB Biopharma SRL · An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

    ClinicalTrials.gov · NCT06668181 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Oct 21, 2024

    Psoriatic Arthritis · COMPLETED · sponsor: UCB Biopharma SRL · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

    ClinicalTrials.gov · NCT06624228 (opens the source filing in a new tab)

  6. Trial

    PHASE3 registered

    Aug 13, 2019

    Psoriatic Arthritis · COMPLETED · sponsor: UCB Biopharma SRL · A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

    ClinicalTrials.gov · NCT04009499 (opens the source filing in a new tab)

  7. Trial

    PHASE3 registered

    Apr 25, 2019

    Ankylosing Spondylitis · COMPLETED · sponsor: UCB Biopharma SRL · A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

    ClinicalTrials.gov · NCT03928743 (opens the source filing in a new tab)

  8. Trial

    PHASE3 registered

    Mar 28, 2019

    Psoriatic Arthritis · COMPLETED · sponsor: UCB Biopharma SRL · A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

    ClinicalTrials.gov · NCT03896581 (opens the source filing in a new tab)

  9. Trial

    PHASE4 registered

    Dec 21, 2016

    Axial Spondyloarthritis (axSpA), Anterior Uveitis (AU) · COMPLETED · sponsor: UCB Biopharma SRL · A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

    ClinicalTrials.gov · NCT03020992 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources